Company: ELV
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0001156039-25-000057
Chunk: 40

Company: Elevance Health, Inc.
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 40
---
 loan commitments to certain equity investees of $501 at March 31, 2025. We do not believe such obligations will materially affect our financial position, results of operations, or cash flows. Vulnerability ConcentrationsFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized by our Board of Directors. Such policies limit the 

-27-

amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which we conduct business. As of March 31, 2025, there were no significant concentrations of financial instruments in a single investee, industry or geographic location.

`12.     Capital Stock 

Stock Incentive PlansA summary of stock option activity for the three months ended March 31, 2025 is as follows:Number ofSharesWeighted-AverageOption Priceper ShareWeighted-AverageRemainingContractualLife (Years)AggregateIntrinsicValueOutstanding at January 1, 20252.9 $361.36 Granted0.6 395.49 Exercised(0.1)209.75 Outstanding at March 31, 20253.4 371.80 6.28$264 Exercisable at March 31, 20252.2 339.92 4.92$239 A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, 2025 is as follows:RestrictedStock Sharesand UnitsWeighted-AverageGrant DateFair Valueper ShareNonvested at January 1, 20251.0 $478.70 Granted0.6 395.49 Vested(0.4)465.96 Nonvested at March 31, 20251.2 442.07 During the three months ended March 31, 2025, we granted approximately 0.2 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2025 to 2027. These grants have been included in the activity shown above but will be subject to adjustment at the